TCGX: SEC Form 425 filed by TCGX Acquisition Corp.
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
TriGemX Bio, a biotech developing the migraine candidate elismetrep, has appointed Daniel Lynch as Chairman of its board.
Directly affected
- TCGX TCGX Acquisition
Named in this report.
Indirectly affected
- No related companies are mapped for this report yet.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| TCGX | +0.40% | +0.05% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
TCGX: SEC Form 425 filed by TCGX Acquisition Corp. Quantisnow
Source: Quantisnow
This story
| Company | When | Move | Status |
|---|---|---|---|
| TCGX | three days earlier | +0.05% | final price |
| TCGX | five days earlier | +0.40% | final price |
How solid “TCGX: SEC Form 425 filed by TCGX Acquisition Corp.” looks
12 out of 100
“TCGX: SEC Form 425 filed by TCGX Acquisition Corp.” scores 12 out of 100. The score uses 1 sources.